CHRNA7 and Alzheimer disease: The NLRP3 inflammasome is definitely an important therapeutic target for delaying AD progression, and it could be speculated that using both 5-HT3 receptor and α7 nAchR antagonists can combat AD pathology and avert AD progression more effectively than either alone.